Effect of olprinone combined with lyophilized recombinant human brain natriuretic peptide on patients with severe heart failure in intensive care unit

Fu Yuhong; Wang Xiaoyue; Wu Junkui; Pan Yonggui; Zhang Haibo

doi:10.3760/j.issn.1673-4777.2024.04.004

Abstract：Objective To investigate the effect of olprinone combined with lyophilized recombinant human brain natriuretic peptide on patients with severe heart failure in intensive care unit(ICU).Methods A total of 114 patients with severe heart failure admitted to ICU of Tangshan Central Hospital from January 2020 to June 2022 were selected as research objects.According to the random number table method,they were divided into the control group and the observation group,with 57 cases in each group.The control group was treated with lyophilized recombinant human brain natriuretic peptide on the basis of conventional treatment,while the observation group was treated with olprinone on the basis of the control group.Both groups of patients were treated continuously for 3 d.The acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ)score and cardiac function improvement were compared between the two groups before treatment,48 h and 72 h after treatment.The length of ICU stay,clinical efficacy,adverse reactions,and 28 d mortality were compared.Results The APACHE Ⅱ scores and the levels of N-terminal pro-brain natriuretic peptide at 48 h and 72 h after treatment in the observation group were lower than those in the control group,and left ventricular ejection fraction and cardiac output were higher than those in the control group(all P＜0.05).The length of ICU stay in the observation group was shorter than that in the control group[(6.5±1.2)dvs(7.3±1.4)d],and the total effective rate was higher than that in the control group[87.7％(50/57)vs 71.9％(41/57)](both P＜0.05).There were no significant differences in the incidence of adverse reactions and 28 d mortality between the two groups(P＞0.05).Conclusion The clinical effect of olprinone combined with lyophilized recombinant human brain natriuretic peptide in the treatment of ICU patients with severe heart failure is significant,which can effectively improve heart failure,shorten the length of hospital stay,and reduce APACHE Ⅱ scores.